Geoffrey McDonough has been appointed President and CEO of Swedish Orphan
Biovitrum AB (Sobi) as of August 15, 2011. He will succeed Kennet Rooth, who has
been acting CEO since January 1, 2011.
Geoffrey McDonough is currently President of Europe, Middle East, and Africa
(EMEA) of Genzyme Corporation, USA, one of the world's leading biotechnology
companies, now part of the French Sanofi Group. In this role Dr. McDonough is
responsible for operations in 55 countries and a portfolio of 15 leading
biotechnology and specialty products. Dr. McDonough has held several leading
positions within Genzyme in the US since 2002, including Senior VP and General
Manager, Personalized Genetic Health, and Senior VP, Global Business Unit
Leader, LSD (Lysosomal Storage Diseases) Therapeutics. Dr. McDonough began his
career at Genzyme in Corporate Development. Prior to joining Genzyme Dr.
McDonough worked as a physician in the US, and also has had experience as a
medical technology entrepreneur and as an adviser for RA Capital Management in
the US.
Geoffrey McDonough was born in 1970 and is a graduate of Harvard Medical School.
He holds a Bachelor of Arts and a Bachelor of Science from University of North
Carolina, where he was awarded the highest honor for his Bachelor's thesis.
"The Board is very pleased to appoint Geoffrey McDonough as new President and
CEO. Geoff is well-recognized for his solid and broad commercial and clinical
expertise and for his background in the orphan drug and niche specialty market.
Geoff will bring his international experience from one of the world's leading
biotechnology and orphan drug-focused companies to lead Sobi toward our vision
of becoming the leading niche specialty pharmaceutical company in Europe," says
Bo Jesper Hansen, Chairman of Sobi.
"I am honored to lead Sobi" says Geoffrey McDonough, "Together we will build on
the strong foundation of a diversified commercial portfolio, excellence in
manufacturing, and a strong pipeline, all focused on the mission to bring
important therapies for rare diseases to patients and families around the
world."
For more information, please contact:
Åsa Stenqvist, VP Communications and Investor Relations
Phone:+46 8 697 21 88
About Swedish Orphan Biovitrum (Sobi)
Sobi is a leading European specialty pharmaceutical company focused on providing
and developing specialty pharmaceuticals for patients with rare diseases and
significant medical needs. The portfolio comprises about 60 marketed products,
as well as projects in late clinical phase. Key therapeutic areas are
hematological diseases, autoimmune diseases, hereditary metabolic disorders and
therapeutic oncology. In 2010 Sobi had revenues of SEK 1.9 billion and
approximately 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. For more information please visitwww.sobi.com
The above information has been made public in accordance with the Swedish
Securities Market Act and/or the Financial Instruments Trading Act. The
information was released for public distribution on June 22, 2011 at 8.30 CET.
[HUG#1525000]
